Novel syngeneic animal model of tobacco-associated oral cancer reveals the activity of in situ anti-CTLA-4
Wang, Z.; Wu, V. H.; Allevato, M. M.; Gilardi, M.; He, Y.; Callejas-Valera, J. L.; Vitale-Cross, L.; Martin, D.; Amornphimoltham, P.; Mcdermott, J.; Goto, Y.; Molinolo, A. A.; Sharabi, A. B.; Cohen, E. E. W.; Chen, Q.; Lyons, G.; Alexandrov, L. B.; Gutkind, J. S.
Show abstract
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide. Tobacco use is the main risk factor for HNSCC, and tobacco-associated HNSCCs have poor prognosis and response to available treatments. Recently approved anti-PD-1 immune checkpoint inhibitors showed limited activity ([≤]20%) in HNSCC, highlighting the need to identify new therapeutic options. For this, mouse models that accurately reflect the complexity of the HNSCC mutational landscape and tumor immune environment are urgently needed. Here, we report the first mouse HNSCC model system that recapitulates the human tobacco-related HNSCC mutanome, in which tumors grow when implanted in the tongue of immunocompetent mice. These HNSCC lesions have similar immune infiltration and response rates to anti-PD-1 ([≤]20%) immunotherapy as human HNSCCs. Remarkably, we found that >70% of HNSCC lesions respond to intratumoral anti-CTLA-4. This syngeneic HNSCC mouse model provides a platform for the development of novel immunotherapeutic options for HNSCC.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer 97%
- Reversible Downregulation of HLA Class I in Adenoid Cystic Carcinoma 95%
- Intratumor Childhood Vaccine-Specific CD4+ T cell Recall Coordinates Antitumor CD8+ T cells and Eosinophils 95%
Similar papers in this journal
- Lymphatic-Preserving Treatment Sequencing with Immune Checkpoint Inhibition Unleashes cDC1-Dependent Antitumor Immunity in HNSCC 97%
- Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers 96%
- Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor resistant HER2-positive breast cancer 95%
Similar papers in this journal
- Endoglin, a novel biomarker and therapeutical target to prevent malignant peripheral nerve sheath tumor growth and metastasis 93%
- High-dimensional and spatial analysis reveals immune landscape dependent progression in cutaneous squamous cell carcinoma 93%
- Preclinical modeling of surgery and steroid therapy for glioblastoma reveals changes in immunophenotype that are associated with tumor growth and outcome 93%
Similar papers in this journal
Similar papers in this journal
- Neoantigen Cancer Vaccines and Different Immune Checkpoint Therapies Each Utilize Both Converging and Distinct Mechanisms that in Combination Enable Synergistic Therapeutic Efficacy 95%
- DNA Damage Response Deficiency Enhances Neuroblastoma Progression and Sensitivity to Combination PARP and ATR Inhibition 94%
- Transcriptional Control of Brain Tumour Stem Cell by a Carbohydrate Binding Protein 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.